Clinical trials: Dose Administration Aids
HIV Infections, Peripheral Nervous System Diseases
Acetyl-L-Carnitine for the Treatment of NRTI-Associated Peripheral Neuropathy
The purpose of this study is to determine if acetyl-L-carnitine (ALC) reduces pain, numbness, and tingling in the feet and legs of patients with nucleoside reverse transcriptase inhibitor (NRTI)-associated peripheral neuropathy.
- Trial name
- NCT00050271
- Testing
- Acetyl-L-carnitine
- Where
- 11 sites in United States, Puerto Rico
- Volunteers
- 27 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
HIV, Human Immunodeficiency Virus
Short-term Disulfiram Administration to Reverse Latent HIV Infection: a Dose Escalation Study
The purpose of this study is to determine the safety, pharmacology and bioactivity of disulfiram in antiretroviral treated HIV-infected adults.
- Trial name
- NCT01944371
- Testing
- Disulfiram
- Where
- 2 sites in United States, Australia
- Volunteers
- 30 people
- Sponsor
- University of California, San Francisco
HIV Infections
TOTEM: Switch From Other Nucleoside Reverse Transcriptase Inhibitors (NRTIs) to Once Daily Truvada
This study looked at lipid changes in human immunodeficiency virus type 1 (HIV-1) infected patients when the nucleoside reverse transcriptase inhibitors (NRTIs) in their existing highly active antiretroviral therapy (HAART)…
- Trial name
- TOTEM (NCT00323492)
- Testing
- Truvada, Current HAART regimen
- Where
- France
- Volunteers
- 92 people
- Sponsor
- Gilead Sciences
HIV Infections
A Dose-Range Finding Clinical Trial Study in Human Immunodeficiency Virus (HIV-1) Infected Treatment-Naive Adults
This is a phase 2b, randomized, multicenter, parallel group, partially blind (to GSK3640254 doses [100, 150 and 200 milligrams {mg}]), active controlled clinical trial.
- Trial name
- DOMINO (NCT04493216)
- Testing
- GSK3640254, ABC/3TC, FTC/TAF
- Where
- 65 sites in United States, Argentina and 9 more
- Volunteers
- 161 people
- Sponsor
- ViiV Healthcare
HIV Infections
A Study of LXR015-1 in HIV-Infected Patients
To determine and compare the safety and tolerability of 3 doses of LXR015-1 in HIV-infected patients.
- Trial name
- NCT00002365
- Testing
- LXR015-1
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- LXR Biotechnology
HIV Infections
A Multicenter, Prospective, Randomized, Double-Blind, Placebo-Controlled Trial of Three Preparations of Low-Dose Oral Alpha Interferon in HIV-Infected Patients With CD4+ Counts >= 50 and <= 350 Cells/mm3
To evaluate the effects of three preparations of low-dose oral interferon alpha (i.e., Alferon LDO, Veldona, and Ferimmune) on HIV symptoms in HIV-infected patients.
- Trial name
- NCT00000844
- Testing
- Interferon alfa-n3, Interferon alfa-n1
- Where
- 15 sites in United States
- Volunteers
- 560 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Chronic Myeloproliferative Disorders, Drug/Agent Toxicity by Tissue/Organ
Combination Chemotherapy Plus Amifostine in Treating Patients With Advanced Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumors from dividing so they stop growing or die. Chemoprotective drugs, such as amifostine, may protect normal cells from the side effects of chemotherapy.
- Conditions
- Chronic Myeloproliferative Disorders, Drug/Agent Toxicity by Tissue/Organ, Leukemia, Lymphoma
- Trial name
- NCT00004036
- Testing
- sargramostim, amifostine trihydrate, carboplatin
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- The Cleveland Clinic
HIV Infections
The Safety and Effectiveness of Three Anti-HIV Drug Combinations in HIV-Infected Patients Who Have Taken AZT
To evaluate the safety and efficacy of low and high doses of lamivudine ( 3TC ) in combination with zidovudine ( AZT ) and zalcitabine ( dideoxycytidine; ddC ) in combination with AZT.
- Trial name
- NCT00002436
- Testing
- Lamivudine, Zidovudine, Zalcitabine
- Where
- 22 sites in United States, Canada and 1 more
- Volunteers
- 325 people
- Sponsor
- Glaxo Wellcome
HIV
Intermittent ART in Primary HIV Infection
Interventions during primary HIV infection (PHI) can modify the immune control and the clinical evolution during the chronic phase.
- Trial name
- PHI-IL2 (NCT02300623)
- Testing
- Antiretroviral therapy plus Interleukin-2, Antiretroviral therapy alone
- Where
- Spain
- Volunteers
- 12 people
- Sponsor
- Juan A. Arnaiz
Trauma, Nervous System
Northwest Therapies Trauma Psilocybin Study Compassionate Use Study
The on-boarding of unregulatable trauma in the United States has reached 20%, which is 1/5 of the population. A population of this magnitude, by definition has now reached an epidemic classification.
- Trial name
- NWTTPS (NCT05042466)
- Testing
- Trauma
- Where
- United States
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- NWTraumatherapies
HIV Infections
An Open Label Safety Study of Tipranavir Co-administered With Low-dose Ritonavir in Patients With Advanced HIV-1 Infection and Limited Treatment Options.
The purpose of this Open Label Safety Study is to provide access to and evaluate the safety and tolerability of TPV/r in treatment-experienced patients with advanced HIV-1 infection who have failed at least two PI-containing…
- Trial name
- NCT00933205
- Testing
- Tipranavir
- Where
- 215 sites in Belgium, Brazil and 7 more
- Sponsor
- Boehringer Ingelheim
Chronic Myeloproliferative Disorders, Leukemia
Combination Chemotherapy in Treating Patients With Advanced Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells.
- Conditions
- Chronic Myeloproliferative Disorders, Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm
- Trial name
- NCT00003331
- Testing
- fluorouracil, leucovorin calcium, topotecan hydrochloride
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- NYU Langone Health
Lymphoma
Chemotherapy and Radiation Therapy in Treating Patients With HIV-Related Primary Central Nervous System Lymphoma
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining radiation therapy with chemotherapy may kill more tumor cells.
- Trial name
- NCT00003261
- Testing
- methotrexate, zidovudine, neoadjuvant therapy
- Where
- Italy
- Volunteers
- 14 people
- Sponsor
- Centro di Riferimento Oncologico - Aviano
HIV Infections, Lipodystrophy
TH9507 in Patients With HIV-Associated Lipodystrophy
HIV lipodystrophy affects a significant proportion of patients treated with combination antiretroviral therapy (ART) and is characterized by excess visceral fat accumulation and loss of extremity and subcutaneous fat, in…
- Trial name
- NCT00123253
- Testing
- TH9507
- Where
- 42 sites in United States, Canada
- Volunteers
- 412 people
- Sponsor
- Theratechnologies
HIV
Assess the Effectiveness and Safety of Lipovirtide Combined With Nucleoside Drugs in HIV-infected Patients.
A randomized, controlled, open-label, dose-exploration study to assess the effectiveness and safety of Lipovirtide combined with nucleoside drugs in HIV-infected patients who have not received antiviral treatment before.
- Trial name
- NCT06061536
- Testing
- Lipovirtide 10mg, Lipovirtide 40mg, Lipovirtide 60mg
- Where
- China
- Volunteers
- 64 people
- Sponsor
- Shanxi Kangbao Biological Product Co., Ltd.
AIDS
Evaluation of the Immune Response of a HIV Candidate Vaccine After Administration of One Chloroquine Dose
The purpose of this study is to evaluate the safety and reactogenicity of one booster dose of a HIV candidate vaccine after administration of one oral dose of chloroquine.
- Trial name
- NCT00972725
- Testing
- GSK Biologicals' HIV vaccine (732461), Chloroquine
- Where
- Belgium
- Volunteers
- 28 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
HIV, Zidovudine Adverse Reaction
Safety of Reduced Dose Zidovudine (AZT) Compared With Standard Dose AZT in Antiretroviral-naïve HIV-infected Patients
The primary objective of the study is to compare the tolerance and safety between a low-dose Zidovudine (AZT) containing regimen (200 mg BID) and a standard dosage (300 mg BID) in HIV patients initiating a first line…
- Trial name
- AZTlowdose (NCT01540240)
- Testing
- Zidovudine
- Where
- Cameroon
- Volunteers
- 136 people
- Sponsor
- University Hospital, Geneva
Cryptosporidiosis, HIV Infections
A Study of Letrazuril in the Treatment of AIDS-Related Diarrhea
To determine the pharmacokinetic profile of single doses of letrazuril in patients with AIDS-related cryptosporidial diarrhea; to determine the dose proportionality of single escalating doses of letrazuril; to determine…
- Trial name
- NCT00001018
- Testing
- Letrazuril
- Where
- 4 sites in United States
- Volunteers
- 32 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
HIV-1
Open Label Study of 908/RTV in Combination With Other PIs for the Treatment of Multi PI-Experienced HIV Subjects
For HIV-infected individuals with highly resistant viruses, higher drug levels may be required to block the virus. This study investigates that concept by comparing the efficacy of standard fosamprenavir/ritonavir to an increased…
- Trial name
- NCT00144833
- Testing
- fosamprenavir/ritonavir (700mg/100mg BID), fosamprenavir/ritonavir (1400mg/100mg BID), fosamprenavir/lopinavir/ritonavir (1400mg/533mg/100mg BID)
- Where
- 42 sites in Australia, Belgium and 7 more
- Volunteers
- 150 people
- Sponsor
- GlaxoSmithKline
HIV Infections
Phase 2 Safety and Efficacy Study of Bevirimat Functional Monotherapy in HIV Treatment-Experienced Patients for 2 Weeks*
The purpose of this study is to evaluate antiretroviral activity of up to five different oral doses administered for two weeks of bevirimat versus placebo in HIV treatment experienced patients, who have documented genotypic…
- Trial name
- NCT00511368
- Testing
- Bevirimat
- Where
- 18 sites in United States
- Volunteers
- 92 people
- Sponsor
- Myrexis Inc.